S27-2 The Promise of Molecular Analysis in the Evaluation of Indeterminate Nodules

Program: Symposia
Session: S27-Nodular Thyroid Disease: Understanding and Assessing Risk
Supported by Genzyme, a Sanofi company
Sunday, June 16, 2013: 9:00 AM-10:30 AM
Presentation Start Time: 9:30 AM
Room 103 (Moscone Center)
Erik Alexander*
Brigham and Women's Hospital
Talk Description:

Thyroid nodules are common; most are benign. The standard evaluation involves fine needle aspiration, though over 30% may return adequate but cytologically indeterminate. In such cases, surgery is often recommended, though over 50% of cases prove benign thus submitting patients to unnecessary risk, cost, and morbidity. Recently, robust molecular markers have been developed and validated for use on such patients. The have led to a paradigm shift in clinical care. This clinical arena, and an up to date analysis of the state of the art, will be discussed.